NASDAQ:CEMI - Chembio Diagnostics Stock Price, Price Target & More

$7.90 +0.05 (+0.64 %)

(As of 04/20/2018 04:00 PM ET)

Previous Close$7.90

Today's Range$7.85 - $7.90

52-Week Range$5.70 - $9.20

Volume2,070 shs

Average Volume9,847 shs

Market Capitalization$111.18 million

P/E Ratio-15.19

Dividend YieldN/A

Beta1.18

About Chembio Diagnostics (NASDAQ:CEMI)

Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or monitor diseases. It offers tests for HIV and Syphilis, and Zika virus. The company also develops tests for malaria, Dengue virus, chikungunya virus, Ebola, Lassa, Marburg, leptospirosis, Rickettsia typhi, Burkholderia pseudomallei, and Orientia tsutsugamushi. It sells its products under the STAT-PAK, SURE CHECK, STAT VIEW, or DPP trademarks, as well as under the private labels of its marketing partners to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. The company has collaboration agreements with Concussion Science Group Division of Perseus Science Group LLC for the development of a POC diagnostic test for traumatic brain injury; and international diagnostics company to develop a POC diagnostic test for a specific type of cancer, as well as with AstraZeneca for the development of a POC assay for a novel biomarker. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Medford, New York.

Receive CEMI News and Ratings via Email

Sign-up to receive the latest news and ratings for CEMI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

SymbolNASDAQ:CEMI

CUSIPN/A

Webwww.chembio.com

Phone631-924-1135

Debt

Debt-to-Equity Ratio0.01%

Current Ratio3.51%

Quick Ratio2.08%

Price-To-Earnings

Trailing P/E Ratio-15.19

Forward P/E Ratio-26.33

P/E GrowthN/A

Sales & Book Value

Annual Sales$24.01 million

Price / Sales4.66

Cash FlowN/A

Price / CashN/A

Book Value$1.06 per share

Price / Book7.45

Profitability

EPS (Most Recent Fiscal Year)($0.52)

Net Income$-6,370,000.00

Net Margins-27.56%

Return on Equity-41.95%

Return on Assets-33.40%

Miscellaneous

Employees165

Outstanding Shares14,160,000

How to Become a New Pot Stock Millionaire

Chembio Diagnostics (NASDAQ:CEMI) Frequently Asked Questions

What is Chembio Diagnostics' stock symbol?

Chembio Diagnostics trades on the NASDAQ under the ticker symbol "CEMI."

How were Chembio Diagnostics' earnings last quarter?

Chembio Diagnostics (NASDAQ:CEMI) posted its quarterly earnings data on Thursday, March, 8th. The company reported ($0.16) earnings per share for the quarter, missing analysts' consensus estimates of ($0.10) by $0.06. The firm earned $5.99 million during the quarter, compared to analysts' expectations of $5.66 million. Chembio Diagnostics had a negative net margin of 27.56% and a negative return on equity of 41.95%. View Chembio Diagnostics' Earnings History.

Who are some of Chembio Diagnostics' key competitors?

Some companies that are related to Chembio Diagnostics include Fortress Biotech (FBIO), Verona Pharma (VRNA), Tyme Technologies (TYME), VBI Vaccines (VBIV), Verastem (VSTM), Tocagen (TOCA), Evolus (EOLS), Menlo Therapeutics (MNLO), Scpharmaceuticals (SCPH), Marinus Pharmaceuticals (MRNS), Ra Pharmaceuticals (RARX), POXEL (PXXLF), Xoma (XOMA), Teligent (TLGT), Summit Therapeutics (SMMT), Spero Therapeutics (SPRO), Zafgen (ZFGN) and Nabriva Therapeutics (NBRV).

Who are Chembio Diagnostics' key executives?

Chembio Diagnostics' management team includes the folowing people:

Mr. John J. Sperzel III, B.Sc., CEO, Pres & Director (Age 54)
Mr. Javan Esfandiari, Chief Science & Technology Officer and Exec. VP (Age 51)
Mr. Michael K. Steele, VP of Sales, Marketing & Bus. Devel. (Age 53)
Ms. Sharon Klugewicz, Pres of Americas Region (Age 50)
Mr. Neil A. Goldman, Exec. VP & CFO

Has Chembio Diagnostics been receiving favorable news coverage?

Press coverage about CEMI stock has trended somewhat positive this week, Accern Sentiment Analysis reports. The research group ranks the sentiment of news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Chembio Diagnostics earned a coverage optimism score of 0.12 on Accern's scale. They also gave press coverage about the company an impact score of 48.08 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

How do I buy shares of Chembio Diagnostics?

Shares of CEMI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Chembio Diagnostics' stock price today?

One share of CEMI stock can currently be purchased for approximately $7.90.

How big of a company is Chembio Diagnostics?

Chembio Diagnostics has a market capitalization of $111.18 million and generates $24.01 million in revenue each year. The company earns $-6,370,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis. Chembio Diagnostics employs 165 workers across the globe.

How can I contact Chembio Diagnostics?

Chembio Diagnostics' mailing address is 3661 HORSEBLOCK ROAD, MEDFORD NY, 11763. The company can be reached via phone at 631-924-1135 or via email at [email protected]

MarketBeat Community Rating for Chembio Diagnostics (CEMI)

Community Ranking:		2.4 out of 5 ( )
Outperform Votes:		74 (Vote Outperform)
Underperform Votes:		82 (Vote Underperform)
Total Votes:		156

MarketBeat's community ratings are surveys of what our community members think about Chembio Diagnostics and other stocks. Vote "Outperform" if you believe CEMI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CEMI will underperform the S&P 500 over the long term. You may vote once every thirty days.

Chembio Diagnostics (NASDAQ:CEMI) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	N/A	N/A	N/A	Buy
Consensus Rating Score:	N/A	N/A	N/A	3.00
Ratings Breakdown:	0 Sell Rating(s) 0 Hold Rating(s) 0 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 0 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 0 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	N/A	N/A	N/A	$9.00
Price Target Upside:	N/A	N/A	N/A	34.33% upside

Chembio Diagnostics (NASDAQ:CEMI) Consensus Price Target History

Price Target History for Chembio Diagnostics (NASDAQ:CEMI)

Chembio Diagnostics (NASDAQ:CEMI) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
11/11/2016	Benchmark	Set Price Target	Buy	$9.00	N/A

(Data available from 4/21/2016 forward)

Chembio Diagnostics (NASDAQ:CEMI) Earnings History and Estimates Chart

Earnings by Quarter for Chembio Diagnostics (NASDAQ:CEMI)

Chembio Diagnostics (NASDAQ:CEMI) Earnings Estimates

2018 EPS Consensus Estimate: ($0.30)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	1	($0.10)	($0.10)	($0.10)
Q2 2018	1	($0.08)	($0.08)	($0.08)
Q3 2018	1	($0.08)	($0.08)	($0.08)
Q4 2018	1	($0.04)	($0.04)	($0.04)

Chembio Diagnostics (NASDAQ CEMI) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
3/8/2018	Q4 2017	($0.10)	($0.16)	$5.66 million	$5.99 million	View	Listen
11/8/2017	Q3 2017	($0.11)	($0.05)	$5.65 million	$7.59 million	View	N/A
8/9/2017	Q2 2017	($0.1650)	($0.18)	$4.96 million	$2.89 million	View	Listen
5/9/2017	Q1 2017	($0.1950)	($0.1320)	$4.88 million	$5.43 million	View	Listen
3/7/2017	Q4 2016	($0.15)	($0.21)	$4.44 million	$4.26 million	View	Listen
11/10/2016	Q3 2016	($0.17)	($0.19)	$3.76 million	$3.75 million	View	N/A
8/11/2016	Q2	($0.11)	($0.86)	$6.72 million	$3.27 million	View	Listen
5/12/2016	Q1	($0.09)	($0.03)	$4.83 million	$6.60 million	View	Listen
3/8/2016	Q4	($0.09)	($0.07)	$6.56 million	$4.42 million	View	N/A
11/12/2015	Q3	($0.09)	($0.05)	$6.77 million	$6.89 million	View	Listen
8/6/2015	Q2	($0.03)	($0.07)	$7.53 million	$6.72 million	View	N/A
5/7/2015	Q115	($0.08)	($0.07)	$5.20 million	$6.20 million	View	N/A
3/5/2015	Q414	($0.04)	($0.05)	$7.10 million	$7.10 million	View	N/A
11/6/2014	Q3 2014	($0.03)	($0.03)	$7.71 million	$7.31 million	View	N/A
8/7/2014	Q2	($0.02)	($0.02)	$6.25 million	$7.42 million	View	N/A
5/8/2014	Q1 2014	($0.02)	($0.02)	$6.87 million	$5.81 million	View	N/A
3/6/2014	Q413	$0.04	($0.03)	$7.05 million	$7.86 million	View	N/A
11/7/2013	Q3 2013	$0.06	$0.07	$8.59 million	$9.62 million	View	N/A
8/8/2013	Q2 2013	($0.04)	($0.03)	$5.56 million	$5.39 million	View	N/A
5/9/2013	Q1 2013	$0.06	$0.04	$7.47 million	$6.31 million	View	N/A
3/7/2013	Q4 2012	$0.07	$0.06			View	N/A
11/13/2012	Q312	$0.04	($0.04)	$6.11 million	$5.01 million	View	N/A
8/9/2012		$0.05	$0.04			View	N/A
5/8/2012	Q1 2012	$0.08	$0.05			View	N/A
3/8/2012	Q4 2011	$0.08	$0.06			View	N/A
11/3/2011	Q3 2011		$0.06			View	N/A
8/4/2011	Q2 2011		$0.02			View	N/A
5/5/2011	Q1 2011		($0.02)			View	N/A
3/3/2011	Q4 2010		$0.22			View	N/A
11/4/2010	Q3 2010		$0.02			View	N/A
7/29/2010	Q2 2010	($0.08)	$0.07			View	N/A
5/6/2010	Q1 2010		($0.02)			View	N/A
3/5/2010	Q4 2009		$0.02			View	N/A
11/4/2009	Q3 2009		$0.03			View	N/A
5/8/2009	Q1 2009		($0.08)			View	N/A
11/12/2008	Q3 2008	($0.08)	($0.03)			View	N/A
8/4/2008	Q2 2008	($0.08)	($0.08)			View	N/A
3/13/2008	Q4 2007	($0.80)	($2.56)			View	N/A

(Earnings results data provided by Zacks Investment Research)

Chembio Diagnostics (NASDAQ:CEMI) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Chembio Diagnostics (NASDAQ CEMI) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.65%
Institutional Ownership Percentage: 31.23%

Insider Trading History for Chembio Diagnostics (NASDAQ:CEMI)

Institutional Ownership by Quarter for Chembio Diagnostics (NASDAQ:CEMI)

Chembio Diagnostics (NASDAQ CEMI) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/13/2018	Neil A Goldman	CFO	Buy	14,815	$6.75	$100,001.25	14,815
6/28/2017	Norman H Pessin	Insider	Buy	36,250	$5.48	$198,650.00
6/15/2016	Sharon W Klugewicz	COO	Sell	3,000	$8.40	$25,200.00	7,000
6/1/2016	Javan Esfandiari	Insider	Sell	25,000	$8.58	$214,500.00	79,110
5/29/2015	Javan Esfandiari	Insider	Sell	20,000	$4.50	$90,000.00
11/19/2014	Peter Kissinger	Director	Buy	1,800	$4.31	$7,758.00
2/26/2014	Sharon W Klugewicz	COO	Buy	10,000	$3.50	$35,000.00
12/6/2013	Javan Esfandiari	SVP	Sell	10,000	$3.40	$34,000.00
11/11/2013	Lawrence A Siebert	Major Shareholder	Sell	30,000	$3.63	$108,900.00

(Data available from 1/1/2013 forward)

Chembio Diagnostics (NASDAQ CEMI) News Headlines

Source:

Date	Headline
	Chembio Diagnostics (CEMI) Upgraded to Sell at ValuEngine www.americanbankingnews.com - April 10 at 7:51 PM
	Chembio Diagnostics (CEMI) Lifted to "Buy" at ValuEngine www.americanbankingnews.com - April 3 at 5:52 PM
	Edited Transcript of CEMI earnings conference call or presentation 8-Mar-18 9:30pm GMT finance.yahoo.com - March 30 at 9:47 AM
	Q1 2018 Earnings Estimate for Chembio Diagnostics Inc Issued By Zacks Investment Research (CEMI) www.americanbankingnews.com - March 16 at 8:37 AM
	CEMI: Q4 2017: Strategic Successes and Recent Wins Sets Up 2018 To Be Another Strong Year finance.yahoo.com - March 14 at 10:44 AM
	Chembio Diagnostics (CEMI) Announces Earnings Results www.americanbankingnews.com - March 9 at 2:03 PM
	Chembio Diagnostics Reports Fourth Quarter and Full Year 2017 Financial Results finance.yahoo.com - March 8 at 5:06 PM
	Neil A. Goldman Purchases 14,815 Shares of Chembio Diagnostics Inc (CEMI) Stock www.americanbankingnews.com - February 13 at 3:18 PM
	Chembio Diagnostics (CEMI) Prices 1.78M Share Common Offering at $6.75/Sh www.streetinsider.com - February 10 at 8:57 AM
	Chembio Diagnostics Announces Major New Tender Win and Certain Preliminary 2017 Financial Results finance.yahoo.com - February 9 at 9:05 AM
	Chembio Diagnostics Announces Proposed Public Offering of Common Stock finance.yahoo.com - February 9 at 9:05 AM
	Chembio Diagnostics Announces Pricing of its Public Offering of Common Stock finance.yahoo.com - February 9 at 9:05 AM
	ETFs with exposure to Chembio Diagnostics, Inc. : December 28, 2017 finance.yahoo.com - December 28 at 3:57 PM
	Chembio Diagnostics, Inc. :CEMI-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017 finance.yahoo.com - December 27 at 1:55 PM
	Chembio Diagnostics (CEMI) Names Neil A. Goldman as Chief Financial Officer www.streetinsider.com - December 21 at 5:25 PM
	Chembio Diagnostics Announces Completion of U.S. Clinical Trial Evaluating DPP® HIV-Syphilis System finance.yahoo.com - December 21 at 9:23 AM
	Chembio Diagnostics Announces Appointment of Neil A. Goldman as Chief Financial Officer finance.yahoo.com - December 20 at 9:25 AM
	Chembio Diagnostics and AstraZeneca Enter a Collaboration to Develop Point-of-Care Diagnostic Test www.nasdaq.com - December 19 at 9:24 AM
	Chembio Diagnostics and AstraZeneca Enter a Collaboration to Develop Point-of-Care Diagnostic Test finance.yahoo.com - December 19 at 9:24 AM
	Zacks Investment Research Weighs in on Chembio Diagnostics, Inc.'s FY2018 Earnings (CEMI) www.americanbankingnews.com - December 11 at 10:50 AM
	CEMI: Moving PT to $15.5/Share On Upward Revenue Revisions, Comp Multiple Expansion finance.yahoo.com - December 7 at 5:53 PM
	Chembio Receives $4.2 Million in Accounts Receivable Payments from Bio-Manguinhos www.nasdaq.com - December 6 at 9:33 AM
	Chembio Diagnostics (CEMI) Secures $8.5M Commitment from Bio-Manguinhos to Purchase Components for Production of DPP Assays in 2018 www.streetinsider.com - December 6 at 9:33 AM
	Chembio Receives $8.5 Million Commitment from Bio-Manguinhos to Purchase Components for Production of DPP® Assays in Brazil during 2018 finance.yahoo.com - December 5 at 10:04 AM
	CEMI: DPP HIV/Syph, Several DPP Fever Products to Drive 2018 Growth finance.yahoo.com - November 20 at 6:13 PM
	Edited Transcript of CEMI earnings conference call or presentation 8-Nov-17 9:30pm GMT finance.yahoo.com - November 9 at 7:55 PM
	ETFs with exposure to Chembio Diagnostics, Inc. : November 9, 2017 finance.yahoo.com - November 9 at 7:55 PM
	CHEMBIO DIAGNOSTICS, INC. to Host Earnings Call finance.yahoo.com - November 8 at 8:42 PM
	Chembio Diagnostics Reports Third Quarter 2017 Financial Results finance.yahoo.com - November 8 at 8:42 PM
	Investor Network Invites You to the Chembio 2017 Third Quarter Earnings Conference Call and Webcast Live on Wednesday, November 8, 2017 finance.yahoo.com - November 7 at 8:03 PM
	Chembio to Host Conference Call to Discuss Third Quarter 2017 Financial Results feeds.benzinga.com - November 1 at 9:28 AM
	ETFs with exposure to Chembio Diagnostics, Inc. : October 30, 2017 finance.yahoo.com - October 30 at 3:41 PM
	ETFs with exposure to Chembio Diagnostics, Inc. : October 17, 2017 finance.yahoo.com - October 17 at 5:50 PM
	ETFs with exposure to Chembio Diagnostics, Inc. : October 5, 2017 finance.yahoo.com - October 5 at 11:39 AM
	Chembio Diagnostics, Inc. :CEMI-US: Earnings Analysis: Q2, 2017 By the Numbers : October 4, 2017 finance.yahoo.com - October 4 at 12:24 PM
	Chembio Announces Return of President and CEO John Sperzel www.nasdaq.com - October 3 at 2:13 AM
	Chembio Diagnostics Receives FDA Emergency Use Authorization for the First Rapid Zika IgM Test finance.yahoo.com - October 2 at 4:09 PM
	BRIEF-Chembio Diagnostics says CFO Richard Larkin to retire by Dec 31 www.reuters.com - August 17 at 11:24 PM
	Chembio Diagnostics (CEMI) CFO to Retire www.streetinsider.com - August 17 at 6:23 PM
	Chembio Diagnostics Announces Retirement of Chief Financial Officer finance.yahoo.com - August 17 at 6:23 PM
	Chembio Diagnostics' (CEMI) CEO John Sperzel on Q2 2017 Results - Earnings Call Transcript seekingalpha.com - August 11 at 5:29 PM
	Chembio Diagnostics, Inc. (CEMI) Posts Earnings Results, Misses Expectations By $0.02 EPS www.americanbankingnews.com - August 10 at 9:28 PM
	Edited Transcript of CEMI earnings conference call or presentation 9-Aug-17 8:30pm GMT finance.yahoo.com - August 10 at 6:15 PM
	Chembio Diagnostics Reports Second Quarter 2017 Financial Results finance.yahoo.com - August 9 at 5:16 PM
	Investor Network Invites You to the Chembio 2017 Second Quarter Earnings Conference Call and Webcast Live on Wednesday, August 9, 2017 finance.yahoo.com - August 8 at 4:49 PM
	Chembio to Host Conference Call to Discuss Second Quarter 2017 Financial Results finance.yahoo.com - August 3 at 6:35 PM
	Gail S. Page Joins Chembio Diagnostics Board of Directors finance.yahoo.com - July 6 at 6:19 PM
	Chembio Diagnostics (CEMI) DPP Zika System Plus DPP Micro Reader Granted Approval by Brazilian Health Regulatory Agency www.streetinsider.com - July 5 at 10:53 PM
	Chembio’s DPP® Zika System Including the DPP® Micro Reader Approved by Brazil’s Health Regulatory Agency finance.yahoo.com - July 5 at 5:49 PM
	Chembio Diagnostics (CEMI) Diagnostics Announces $21.2M At-The-Market Program www.streetinsider.com - June 27 at 9:31 PM

Chembio Diagnostics (NASDAQ:CEMI) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Chembio Diagnostics (NASDAQ:CEMI) Income Statement, Balance Sheet and Cash Flow Statement

Chembio Diagnostics (NASDAQ CEMI) Stock Chart for Saturday, April, 21, 2018

Loading chart…

This page was last updated on 4/21/2018 by MarketBeat.com Staff